Cancer Stem Cell Markers CD44v9+/CD133- Are Associated with Low Apoptosis in Both Sporadic and Ulcerative Colitis-associated Colorectal Cancers

Overview

Journal Histol Histopathol

Specialties Anatomy & Histology
Pathology

Date 2022 Feb 28

PMID 35224715

Authors

Eriko Nakagomi

Tetuo Mikami

Kimihiko Funahashi

Shinichi Okazumi

Kazutoshi Shibuya

Nobuyuki Hiruta

Yoshinori Igarashi

Affiliations

Soon will be listed here.

Abstract

Objective: To elucidate tumor cell behavior associated with cancer stem cell (CSC) marker expression, the expression of CD133, CD44v9, and ALDH1A1, which are considered markers of CSCs, was examined in sporadic and ulcerative colitis (UC)-associated colorectal tumors.

Methods: A total of 23 cases of sporadic colorectal cancer and 44 cases of adenoma were collected. Additionally, 22 cancer lesions and 38 dysplasia lesions were selected from 28 colectomy cases of UC with neoplastic lesions. Lesions were examined by immunohistochemistry using primary antibodies against CD133, CD44v9, ALDH1A1, Ki-67, cleaved-Caspase 3, and p53.

Results: CD133, CD44v9, and ALDH1A1 showed higher expression in both sporadic and UC-associated tumors than in the normal mucosa. ALDH1A1 expression in sporadic cancer was higher in the right colon than in the left colon (p=0.0089). ALDH1A1 expression in UC-associated cancer was higher in those with longer disease duration than in those with shorter disease duration (p=0.019). The CD44v9+/CD133- region had fewer cleaved-Caspase 3 positive cells in both sporadic and UC-associated cancers. In sporadic cancer, CD133+/ALDH1A1+ regions had fewer apoptotic cells than CD133+/ALDH1A1- regions, while CD133+/ALDH1A1- regions were less proliferative than CD133+/ALDH1A1+ regions in UC-associated cancer.

Conclusion: CD44+/CD133- regions were commonly associated with low apoptosis in sporadic and UC-associated cancers; thus, these were considered target areas for CSCs. Additionally, the combination of markers comprising CSCs may differ between sporadic and UC-associated cancers.

Citing Articles

Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?.

Brockmueller A, Buhrmann C, Moravejolahkami A, Shakibaei M J Adv Res. 2024; 66:181-195.

PMID: 38190940 PMC: 11674784. DOI: 10.1016/j.jare.2024.01.005.

References

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Carpentino J, Hynes M, Appelman H, Zheng T, Steindler D, Scott E . Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009; 69(20):8208-15. PMC: 2776663. DOI: 10.1158/0008-5472.CAN-09-1132. View

Castano-Milla C, Chaparro M, Gisbert J . Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(7):645-59. DOI: 10.1111/apt.12651. View

Chu P, Clanton D, Snipas T, Lee J, Mitchell E, Nguyen M . Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer. 2008; 124(6):1312-21. DOI: 10.1002/ijc.24061. View

Du L, Wang H, He L, Zhang J, Ni B, Wang X . CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008; 14(21):6751-60. DOI: 10.1158/1078-0432.CCR-08-1034. View

Galizia G, Gemei M, Del Vecchio L, Zamboli A, Di Noto R, Mirabelli P . Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012; 147(1):18-24. DOI: 10.1001/archsurg.2011.795. View

Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K . CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 2008; 15(10):2927-33. DOI: 10.1245/s10434-008-0074-0. View

Holah N, Aiad H, Asaad N, Elkhouly E, Lasheen A . Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study. J Clin Diagn Res. 2017; 11(1):EC17-EC23. PMC: 5324418. DOI: 10.7860/JCDR/2017/22671.9291. View

10.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A . CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008; 99(8):1285-9. PMC: 2570510. DOI: 10.1038/sj.bjc.6604664. View

11.

Huang E, Hynes M, Zhang T, Ginestier C, Dontu G, Appelman H . Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009; 69(8):3382-9. PMC: 2789401. DOI: 10.1158/0008-5472.CAN-08-4418. View

12.

Karunanithi S, Levi L, DeVecchio J, Karagkounis G, Reizes O, Lathia J . RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and Mediates High-Fat Diet-Induced Colon Carcinogenesis. Stem Cell Reports. 2017; 9(2):438-450. PMC: 5549806. DOI: 10.1016/j.stemcr.2017.06.002. View

13.

Khorrami S, Zavaran Hosseini A, Mowla S, Malekzadeh R . Verification of ALDH Activity as a Biomarker in Colon Cancer Stem Cells-Derived HT-29 Cell Line. Iran J Cancer Prev. 2015; 8(5):e3446. PMC: 4667234. DOI: 10.17795/ijcp-3446. View

14.

Kimura Y, Goi T, Nakazawa T, Hirono Y, Katayama K, Urano T . CD44variant exon 9 plays an important role in colon cancer initiating cells. Oncotarget. 2013; 4(5):785-91. PMC: 3742838. DOI: 10.18632/oncotarget.1048. View

15.

Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A . Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008; 99(8):1578-83. PMC: 11159232. DOI: 10.1111/j.1349-7006.2008.00849.x. View

16.

Leowardi C, Schneider M, Hinz U, Harnoss J, Tarantino I, Lasitschka F . Prognosis of Ulcerative Colitis-Associated Colorectal Carcinoma Compared to Sporadic Colorectal Carcinoma: A Matched Pair Analysis. Ann Surg Oncol. 2015; 23(3):870-6. DOI: 10.1245/s10434-015-4915-3. View

17.

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

18.

Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S . The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011; 121(7):2723-35. PMC: 3223826. DOI: 10.1172/JCI44745. View

19.

Moreira I, Pinto F, Gomes C, Campos D, Reis C . Impact of Truncated -glycans in Gastric-Cancer-Associated CD44v9 Detection. Cells. 2020; 9(2). PMC: 7072479. DOI: 10.3390/cells9020264. View

20.

Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y . Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011; 31(2):495-500. View